Get started
Author

Thierry Chatellier

Observed names: Chatellier, Thierry, T. Chatelier, T. Chatellier, T. chatellier
ORCID: 0009-0009-3679-1645
Observed ORCID: 0009-0009-3679-1645
OpenAlex ID: A5103118448
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials
2018 · Thomas Aparicio, Michel Ducreux, et al. · European Journal of Cancer · 46
PDF
Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab
2021 · Mathilde Bureau, Thierry Chatellier, et al. · Cancer Immunology Immunotherapy · 20
Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study
2024 · Elvire Pons-Tostivint, Remy Ezzedine, et al. · Lung Cancer · 18
PDF
A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients
2023 · Marie Porte, Adrien Vaudron, et al. · Clinical Lung Cancer · 14
PDF
Nivolumab‐induced celiac‐like enteropathy in patient with metastatic renal cell carcinoma: Case report and review of the literature
2019 · Lucie Duval, Sarah Habes, et al. · Clinical Case Reports · 13
PDF
Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial
2022 · Bernadette de Rauglaudre, Camille Sibertin-Blanc, et al. · Therapeutic Advances in Medical Oncology · 5
Second-line treatment outcomes following first-line chemotherapy plus immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC): A multicenter study.
2024 · Elvire Pons-Tostivint, Remy Ezzedine, et al. · Journal of Clinical Oncology · 1
PDF
2002P A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
2023 · M. Porte, A. Vaudron, et al. · Annals of Oncology · 1
676P ATHENA: A multicenter phase II of atezolizumab (A) and bevacizumab (B) in patients (pts) with recurrent or metastatic squamous-cell carcinoma of the head and neck (R/M HNSCC) - The HPV-negative cohort
2022 · J. Fayette, E.B. Saada, et al. · Annals of Oncology · 1
PDF
190P EORTC-SPECTA Arcagen project: Results of the prospective rare thoracic tumors cohort
2023 · M. Tagliamento, M. Morfouace, et al. · Journal of Thoracic Oncology
PDF
1295P Prognostic impact of baseline tumor size (BTS) on survival outcomes in patients (pts) with untreated advanced non-small cell lung cancer (NSCLC), PD-L1 ≥50%, treated with pembrolizumab alone
2021 · M. Bureau, T. Chatelier, et al. · Annals of Oncology
2145 Masitinib plus FOLFIRI for second-line treatment of metastatic colorectal cancer: 2-year follow-up of phase open label trial
2015 · J. Taieb, C. Borg, et al. · European Journal of Cancer
Works count: 14
Citation count: 119
H-index: 5
I10-index: 5
Year
Topic
Type